Roche's multiple sclerosis drug fenebrutinib meets goal in late-stage trial reut.rs/4rA3MjE
Roche's multiple sclerosis drug fenebrutinib meets goal in late-stage trial
Swiss pharmaceutical company Roche said on Saturday its experimental multiple sclerosis drug fenebrutinib met the main goal in a late-stage trial in patients with primary progressive multiple sclerosis, a rare form of the disease with few treatment options.
reut.rs
February 7, 2026 at 9:00 PM
Roche's multiple sclerosis drug fenebrutinib meets goal in late-stage trial reut.rs/4rA3MjE
A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis
#MSchat #Neurology #MultipleSclerosis #ClinicalTrial #botsFightMS
#MSchat #Neurology #MultipleSclerosis #ClinicalTrial #botsFightMS
August 25, 2024 at 6:58 PM
A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis
#MSchat #Neurology #MultipleSclerosis #ClinicalTrial #botsFightMS
#MSchat #Neurology #MultipleSclerosis #ClinicalTrial #botsFightMS
New data on fenebrutinib. It had similar efficacy to ocrevus in primary progressive MS in the FENTREPID trial and was superior to aubagio in relapsing MS in the FENHANCE trial. www.fiercebiotech.com/biotech/roch...
Roche reports phase 3 multiple sclerosis wins for BTK inhibitor, succeeding where rivals failed
Roche has
www.fiercebiotech.com
November 11, 2025 at 4:19 AM
New data on fenebrutinib. It had similar efficacy to ocrevus in primary progressive MS in the FENTREPID trial and was superior to aubagio in relapsing MS in the FENHANCE trial. www.fiercebiotech.com/biotech/roch...
Have you checked out our latest podcast on fenebrutinib for relapsing multiple sclerosis yet?
Listen here: tinyurl.com/59nvbxam
Read the associated paper here: tinyurl.com/3r5dv99j
Listen here: tinyurl.com/59nvbxam
Read the associated paper here: tinyurl.com/3r5dv99j
July 18, 2025 at 3:17 PM
Have you checked out our latest podcast on fenebrutinib for relapsing multiple sclerosis yet?
Listen here: tinyurl.com/59nvbxam
Read the associated paper here: tinyurl.com/3r5dv99j
Listen here: tinyurl.com/59nvbxam
Read the associated paper here: tinyurl.com/3r5dv99j
This document provides a detailed overview of emerging treatments for multiple sclerosis (MS).
The field is moving toward personalized medicine with biomarker-driven treatment selection, CNS-penetrant therapies, and high-efficacy-first approaches to slow progression.
docs.google.com/document/d/e...
The field is moving toward personalized medicine with biomarker-driven treatment selection, CNS-penetrant therapies, and high-efficacy-first approaches to slow progression.
docs.google.com/document/d/e...
June 12, 2025 at 7:50 PM
This document provides a detailed overview of emerging treatments for multiple sclerosis (MS).
The field is moving toward personalized medicine with biomarker-driven treatment selection, CNS-penetrant therapies, and high-efficacy-first approaches to slow progression.
docs.google.com/document/d/e...
The field is moving toward personalized medicine with biomarker-driven treatment selection, CNS-penetrant therapies, and high-efficacy-first approaches to slow progression.
docs.google.com/document/d/e...
Signal or noise? > Genentech’s Fenebrutinib Shows Unprecedented Positive Phase
III Results as the Potential First and Only BTK Inhibitor in Both
Relapsing and Primary Progressive Multiple Sclerosis >> Comment below! #AI #industry40 #IoT #mhealth #healthtech
III Results as the Potential First and Only BTK Inhibitor in Both
Relapsing and Primary Progressive Multiple Sclerosis >> Comment below! #AI #industry40 #IoT #mhealth #healthtech
Genentech’s Fenebrutinib Shows Unprecedented Positive Phase
III Results as the Potential First and Only BTK Inhibitor in Both
Relapsing and Primary Progressive Multiple Sclerosis
– The first (FENhance 2) of two pivotal RMS studies met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses compared to teriflunomide – – In a pivotal PPMS study (FENtrepid), fenebrutinib slowed disability progression at least as effectively as Ocrevus, the only approved therapy in PPMS – – Full data from both studies will …
dlvr.it
November 10, 2025 at 6:32 AM
Signal or noise? > Genentech’s Fenebrutinib Shows Unprecedented Positive Phase
III Results as the Potential First and Only BTK Inhibitor in Both
Relapsing and Primary Progressive Multiple Sclerosis >> Comment below! #AI #industry40 #IoT #mhealth #healthtech
III Results as the Potential First and Only BTK Inhibitor in Both
Relapsing and Primary Progressive Multiple Sclerosis >> Comment below! #AI #industry40 #IoT #mhealth #healthtech
Le #Fénébrutinib de #Genentech montre des résultats positifs sans précédent en phase III en tant que premier et seul inhibiteur potentiel de la #BTK dans la #ScléroseEnPlaques ( #RMS) progressive récurrente et primaire
www.gene.com/media/press-...
www.gene.com/media/press-...
Genentech: Press Releases | Sunday, Nov 9, 2025
Discover the latest news about our company, our products, our policies, and our people.
www.gene.com
November 10, 2025 at 6:39 AM
Le #Fénébrutinib de #Genentech montre des résultats positifs sans précédent en phase III en tant que premier et seul inhibiteur potentiel de la #BTK dans la #ScléroseEnPlaques ( #RMS) progressive récurrente et primaire
www.gene.com/media/press-...
www.gene.com/media/press-...
💊Společnost Genentech oznámila přelomové a "bezprecedentní" výsledky. Její experimentální lék fenebrutinib je prvním perorálním BTK inhibitorem, který úspěšně splnil hlavní cíle v klinických studiích Fáze 3 jak u relabujících forem RS (kde byl lepší než...
Více:⬇️
roztrouseni.cz/prulom-pro-b...
Více:⬇️
roztrouseni.cz/prulom-pro-b...
Průlom pro BTK inhibitory: Fenebrutinib jako první uspěl ve Fázi 3 u relabující i progresivní RS | roztroušení
Společnost Genentech oznámila přelomové a
roztrouseni.cz
November 15, 2025 at 11:17 AM
💊Společnost Genentech oznámila přelomové a "bezprecedentní" výsledky. Její experimentální lék fenebrutinib je prvním perorálním BTK inhibitorem, který úspěšně splnil hlavní cíle v klinických studiích Fáze 3 jak u relabujících forem RS (kde byl lepší než...
Více:⬇️
roztrouseni.cz/prulom-pro-b...
Více:⬇️
roztrouseni.cz/prulom-pro-b...
#Roche #primaryprogressiveMS #MS #phase3trial #oralBTKinhibitor #fenebrutinib #primaryprogressivemultiplesclerosis #PPMS #Ocrevus #ocrelizumab #FENtrepidtrial #disabilityprogression #CD20targetingantibody #FENhance1trial #FENhance2trial #clinicalbenefit #diseasemodifyingtherapy
zurl.co/MGaVR
zurl.co/MGaVR
Data builds on Roche's dominance in primary progressive MS
Roche looks on track to add oral BTK inhibitor fenebrutinib to treatment options for primary progressive multiple sclerosis.
pharmaphorum.com
February 10, 2026 at 10:17 AM
NEW ISSUE ALERT!!🗞️🧠 Featuring physiotherapy after stroke, updates to the ILAE seizure classification, focused ultrasound therapy for movement disorders, α-synuclein biomarker assays, fenebrutinib in multiple sclerosis and much more: tinyurl.com/muj5ycp3
#Neurology #Brain
#Neurology #Brain
July 17, 2025 at 2:50 PM
NEW ISSUE ALERT!!🗞️🧠 Featuring physiotherapy after stroke, updates to the ILAE seizure classification, focused ultrasound therapy for movement disorders, α-synuclein biomarker assays, fenebrutinib in multiple sclerosis and much more: tinyurl.com/muj5ycp3
#Neurology #Brain
#Neurology #Brain
Roche senkt in Phase-III-Studie mit Fenebrutinib Rückfallrate bei MS
https://www.awp.ch/sharedarticles?articleid=-1983230117
https://www.awp.ch/sharedarticles?articleid=-1983230117
November 10, 2025 at 6:17 AM
Roche senkt in Phase-III-Studie mit Fenebrutinib Rückfallrate bei MS
https://www.awp.ch/sharedarticles?articleid=-1983230117
https://www.awp.ch/sharedarticles?articleid=-1983230117
www.boursorama.com/bourse/actua...
Roche-Le fénébrutinib contre la SEP atteint l'objectif principal d'un essai de phase avancée
( ce n'est en aucun cas, un médicament pour soigner, uniquement pour retarder l'évolution de la maladie)
Roche-Le fénébrutinib contre la SEP atteint l'objectif principal d'un essai de phase avancée
( ce n'est en aucun cas, un médicament pour soigner, uniquement pour retarder l'évolution de la maladie)
Roche-Le fénébrutinib contre la SEP atteint l'objectif principal d'un essai de phase avancée
Le fabricant suisse de médicaments Roche a déclaré lundi qu'un essai clinique de phase avancée évaluant son candidat médicament contre la sclérose en plaques (SEP), le fenebrutinib, dans le traitement...
www.boursorama.com
November 10, 2025 at 8:30 AM
www.boursorama.com/bourse/actua...
Roche-Le fénébrutinib contre la SEP atteint l'objectif principal d'un essai de phase avancée
( ce n'est en aucun cas, un médicament pour soigner, uniquement pour retarder l'évolution de la maladie)
Roche-Le fénébrutinib contre la SEP atteint l'objectif principal d'un essai de phase avancée
( ce n'est en aucun cas, un médicament pour soigner, uniquement pour retarder l'évolution de la maladie)
🧠August's #EANhighlights:
➡️ GLP-1 RAs reduced IIH impact
➡️ Stroke rehab improved endurance
➡️ Fenebrutinib cut MS lesions 69%
➡️ Lamotrigine heart-safe in elderly
➡️ Tenecteplase post-thrombectomy helped stroke outcomes
🔗Read more: www.eanpages.org/2025/08/12/r...
➡️ GLP-1 RAs reduced IIH impact
➡️ Stroke rehab improved endurance
➡️ Fenebrutinib cut MS lesions 69%
➡️ Lamotrigine heart-safe in elderly
➡️ Tenecteplase post-thrombectomy helped stroke outcomes
🔗Read more: www.eanpages.org/2025/08/12/r...
August 26, 2025 at 10:09 AM
🧠August's #EANhighlights:
➡️ GLP-1 RAs reduced IIH impact
➡️ Stroke rehab improved endurance
➡️ Fenebrutinib cut MS lesions 69%
➡️ Lamotrigine heart-safe in elderly
➡️ Tenecteplase post-thrombectomy helped stroke outcomes
🔗Read more: www.eanpages.org/2025/08/12/r...
➡️ GLP-1 RAs reduced IIH impact
➡️ Stroke rehab improved endurance
➡️ Fenebrutinib cut MS lesions 69%
➡️ Lamotrigine heart-safe in elderly
➡️ Tenecteplase post-thrombectomy helped stroke outcomes
🔗Read more: www.eanpages.org/2025/08/12/r...
#MS_Selfie Breaking News: Fenebrutinib Press Release
My predictions may be correct. What were yours? Is this the game-changer we were hoping for? => gavingiovannoni.substack.com/p/breaking-n...
My predictions may be correct. What were yours? Is this the game-changer we were hoping for? => gavingiovannoni.substack.com/p/breaking-n...
Breaking news: Fenebrutinib Press Release
My predictions may be correct.
gavingiovannoni.substack.com
November 11, 2025 at 7:34 AM
#MS_Selfie Breaking News: Fenebrutinib Press Release
My predictions may be correct. What were yours? Is this the game-changer we were hoping for? => gavingiovannoni.substack.com/p/breaking-n...
My predictions may be correct. What were yours? Is this the game-changer we were hoping for? => gavingiovannoni.substack.com/p/breaking-n...
www.mdpi.com/1422-0067/23...
"SPA was completely abrogated by blood pre-incubation with the reversible Btk-inhibitor (BTKi) fenebrutinib (50 nM), and 3 h after intake of the irreversible BTKi ibrutinib (280 mg) by healthy volunteers."
"SPA was completely abrogated by blood pre-incubation with the reversible Btk-inhibitor (BTKi) fenebrutinib (50 nM), and 3 h after intake of the irreversible BTKi ibrutinib (280 mg) by healthy volunteers."
Spontaneous Platelet Aggregation in Blood Is Mediated by FcγRIIA Stimulation of Bruton’s Tyrosine Kinase
High platelet reactivity leading to spontaneous platelet aggregation (SPA) is a hallmark of cardiovascular diseases; however, the mechanism underlying SPA remains obscure. Platelet aggregation in stir...
www.mdpi.com
February 14, 2025 at 11:27 PM
www.mdpi.com/1422-0067/23...
"SPA was completely abrogated by blood pre-incubation with the reversible Btk-inhibitor (BTKi) fenebrutinib (50 nM), and 3 h after intake of the irreversible BTKi ibrutinib (280 mg) by healthy volunteers."
"SPA was completely abrogated by blood pre-incubation with the reversible Btk-inhibitor (BTKi) fenebrutinib (50 nM), and 3 h after intake of the irreversible BTKi ibrutinib (280 mg) by healthy volunteers."
#SEP #fenebrutinib
#MultipleSclerosis
"Roche revendique des succès cliniques contre la sclérose en plaques"
www.swissinfo.ch/fre/roche-re...
#MultipleSclerosis
"Roche revendique des succès cliniques contre la sclérose en plaques"
www.swissinfo.ch/fre/roche-re...
Roche revendique des succès cliniques contre la sclérose en plaques
La multinationale pharmaceutique Roche assure avoir observé une concrétisation du critère primaire établi pour le premier des deux programmes cliniques avancés sur le médicament fénébrutinib, développ...
www.swissinfo.ch
November 10, 2025 at 9:22 AM
#SEP #fenebrutinib
#MultipleSclerosis
"Roche revendique des succès cliniques contre la sclérose en plaques"
www.swissinfo.ch/fre/roche-re...
#MultipleSclerosis
"Roche revendique des succès cliniques contre la sclérose en plaques"
www.swissinfo.ch/fre/roche-re...
#MS_Selfie Breaking News: Fenebrutinib Press Release
My predictions may be correct. What were yours? Is this the game-changer we were hoping for? => gavingiovannoni.substack.com/p/breaking-n...
My predictions may be correct. What were yours? Is this the game-changer we were hoping for? => gavingiovannoni.substack.com/p/breaking-n...
Breaking news: Fenebrutinib Press Release
My predictions may be correct.
gavingiovannoni.substack.com
November 11, 2025 at 7:35 AM
#MS_Selfie Breaking News: Fenebrutinib Press Release
My predictions may be correct. What were yours? Is this the game-changer we were hoping for? => gavingiovannoni.substack.com/p/breaking-n...
My predictions may be correct. What were yours? Is this the game-changer we were hoping for? => gavingiovannoni.substack.com/p/breaking-n...
www.bernerzeitung.ch/roche-neues-...
"Besonders positiv wirkte sich Fenebrutinib auf die Beweglichkeit und Kraft der oberen Gliedmassen aus, also auf Hände, Arme und Schultern. Gerade diese Fähigkeiten sind für viele alltägliche Tätigkeiten entscheidend."
🥳🥳🥳
"Besonders positiv wirkte sich Fenebrutinib auf die Beweglichkeit und Kraft der oberen Gliedmassen aus, also auf Hände, Arme und Schultern. Gerade diese Fähigkeiten sind für viele alltägliche Tätigkeiten entscheidend."
🥳🥳🥳
Multiple Sklerose: Roche-Wirkstoff bremst aggressive MS erstmals messbar
Fenebrutinib zeigt Wirkung gegen eine MS-Form, die bisher kaum behandelbar war. Besonders die Beweglichkeit der oberen Gliedmassen verbessert sich. Erste Vorteile zeigen sich bereits nach 24 Wochen.
www.bernerzeitung.ch
February 8, 2026 at 8:05 PM
www.bernerzeitung.ch/roche-neues-...
"Besonders positiv wirkte sich Fenebrutinib auf die Beweglichkeit und Kraft der oberen Gliedmassen aus, also auf Hände, Arme und Schultern. Gerade diese Fähigkeiten sind für viele alltägliche Tätigkeiten entscheidend."
🥳🥳🥳
"Besonders positiv wirkte sich Fenebrutinib auf die Beweglichkeit und Kraft der oberen Gliedmassen aus, also auf Hände, Arme und Schultern. Gerade diese Fähigkeiten sind für viele alltägliche Tätigkeiten entscheidend."
🥳🥳🥳
New post: Fenebrutinib in PPMS https://multiple-sclerosis-research.org/2025/11/fenebrutinib-in-ppms/
November 25, 2025 at 12:00 AM
New post: Fenebrutinib in PPMS https://multiple-sclerosis-research.org/2025/11/fenebrutinib-in-ppms/
#Roche has revealed the data behind a positive phase 3 trial for its #oralBTKinhibitor fenebrutinib in primary progressive #multiplesclerosis (PPMS), revealing that it was at least as effective as its blockbuster Ocrevus administered intravenously.
Data builds on Roche's dominance in primary progressive MS
Roche looks on track to add oral BTK inhibitor fenebrutinib to treatment options for primary progressive multiple sclerosis.
buff.ly
February 9, 2026 at 3:30 PM
#Roche has revealed the data behind a positive phase 3 trial for its #oralBTKinhibitor fenebrutinib in primary progressive #multiplesclerosis (PPMS), revealing that it was at least as effective as its blockbuster Ocrevus administered intravenously.
Roche sieht Wirksamkeit vom MS-Kandidaten Fenebrutinib durch Daten bestätigt
Roche hat neue Ergebnisse aus einer zulassungsrelevanten Studie zu dem experimentellen Medikament Fenebrutinib am Fachkongress Actrims in Kalifornien vorgelegt.
https://www.awp.ch/sharedarticles?articleid=-1980578320
Roche hat neue Ergebnisse aus einer zulassungsrelevanten Studie zu dem experimentellen Medikament Fenebrutinib am Fachkongress Actrims in Kalifornien vorgelegt.
https://www.awp.ch/sharedarticles?articleid=-1980578320
Geteilte Artikel
AWP veröffentlicht eine kleine Auswahl an Nachrichten auf den Sozialen Medien. Sie finden uns auf Mastodon unter @[email protected] und auf Twitter unter @awp.de.
www.awp.ch
February 8, 2026 at 9:27 AM
Roche sieht Wirksamkeit vom MS-Kandidaten Fenebrutinib durch Daten bestätigt
Roche hat neue Ergebnisse aus einer zulassungsrelevanten Studie zu dem experimentellen Medikament Fenebrutinib am Fachkongress Actrims in Kalifornien vorgelegt.
https://www.awp.ch/sharedarticles?articleid=-1980578320
Roche hat neue Ergebnisse aus einer zulassungsrelevanten Studie zu dem experimentellen Medikament Fenebrutinib am Fachkongress Actrims in Kalifornien vorgelegt.
https://www.awp.ch/sharedarticles?articleid=-1980578320
Roche's oral BTK inhibitor fenebrutinib is on track for filings next year for #multiplesclerosis after clearing two phase 3 trials.
pharmaphorum.com/news/roches-...
pharmaphorum.com/news/roches-...
Roche's oral MS hope fenebrutinib hits the mark in phase 3
Roche's oral BTK inhibitor fenebrutinib is on track for filings next year for multiple sclerosis after clearing two phase 3 trials
pharmaphorum.com
November 10, 2025 at 1:41 PM
Roche's oral BTK inhibitor fenebrutinib is on track for filings next year for #multiplesclerosis after clearing two phase 3 trials.
pharmaphorum.com/news/roches-...
pharmaphorum.com/news/roches-...
Data from the FENopta trial (fenebrutinib vs. placebo in relapsing MS) open label extension trial. Relapses remained low (annualized relapse rate of 0.04) and 90% with no evidence of disease activity. EDSS (disability) stable. Some had low antibodies. www.physiciansweekly.com/ms-activity-...
MS Activity Remains Low on Long-Term Fenebrutinib - Physician's Weekly
Participants receiving the potent and highly selective BTK inhibitor fenebrutinib maintained low disease activity in the OLE of the FENopta study.
www.physiciansweekly.com
March 28, 2025 at 4:06 PM
Data from the FENopta trial (fenebrutinib vs. placebo in relapsing MS) open label extension trial. Relapses remained low (annualized relapse rate of 0.04) and 90% with no evidence of disease activity. EDSS (disability) stable. Some had low antibodies. www.physiciansweekly.com/ms-activity-...
A Study to Evaluate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis
#MSchat #Neurology #MultipleSclerosis #ClinicalTrial #botsFightMS
#MSchat #Neurology #MultipleSclerosis #ClinicalTrial #botsFightMS
March 22, 2024 at 4:42 PM
A Study to Evaluate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis
#MSchat #Neurology #MultipleSclerosis #ClinicalTrial #botsFightMS
#MSchat #Neurology #MultipleSclerosis #ClinicalTrial #botsFightMS